Application is supported by data from the Phase 3 CARTITUDE-4 study, which showed significant improvement in primary endpoint of progre...
CID is a common and often debilitating toxicity affecting up to 90% of patients receiving chemotherapy. CID can cause dehydration, electrolyte imbalance, m...
As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest co...
Non-invasive cardiac diagnostic company Sensydia announced today that it was awarded a Fast-Track Small Business grant from the National Heart, Lung, and B...
Agilent Technologies Inc. (NYSE: A) announces the 10th anniversary of the Agilent BioTek Cytation 3 cell imaging multimode reader and the Agilent Bio...
Partners are the Hartwig Group at University of California, Berkeley and Lawrence Berkeley National Laboratory jointly led by John Hartwig Three-year co...
-Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon ...
Charles River Laboratories International, Inc. (NYSE: CRL) and Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), annou...
Following a special meeting of its stockholders, Seagen Inc. (Nasdaq: SGEN) today announced that its stockholders voted to approve a proposal to adopt the ...
A type of artificial intelligence (AI), Deep Learning (DL) technology can advance medical imaging capabilities by providing more robust, accurate, and da...
The grant will fund additional patient dosing studies to identify predictive biomarkers of activity and target engagement of TRE-515 in solid tumors. Treth...
HMBD-002, a non-depleting, high-affinity anti-VISTA antibody, possesses key design features enabling robust anti-tumor activity in pr...
INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits by 33% compared to ...
First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma Iovance Biotherapeutics, Inc. (NASDAQ: IOVA...
© 2025 Biopharma Boardroom. All Rights Reserved.
